New Dimeric Tetrapeptide Enkephalin Analogues
Hydrophilic Spacer Length and Configuration Affects Potency and Receptor Selectivity

Janusz Stepiński a, S. William Tam b

a Department of Chemistry, University of Warsaw, ul. Pasteura 1, 02-093 Warsaw, Poland
b The DuPont Merck Pharmaceutical Company, Wilmington, DE, U.S.A.

Z. Naturforsch. 49b, 407–411 (1994); received September 9, 1993

Bivalent Opioids, Enkephalin Analogues, Opioid Receptor Selectivity

Three new bivalent opioid peptide analogues, 1,3-di-(tyrosyl-D-alanyl-glycyl-phenylalanylamido)-2-propanol, 1,4-di-(tyrosyl-D-alanyl-glycyl-phenylalanylamido)-(2 R,3 S)-butanediol and 1,4-di-(tyrosyl-D-alanyl-glycyl-phenylalanylamido)-(2 R,3 R)-butanediol, were synthesized and tested in vitro for μ, δ and κ receptor affinities. They were found to have potent opioid receptor binding activity. The (2 S,3 S)-butanediol bridge configuration yielded high potency and selectivity for δ receptors. It thus appears that changes in the length and configuration of the polyhydroxyl bridge in dimeric enkephalin analogues can produce a shift in receptor selectivity profiles and therefore suggest the possibility of developing more selective drugs.

Introduction

One of the promising possibility of developing new opioid analogues is the synthesis of compounds containing two pharmacophores in one molecule [1–7]. Anallogues called dimeric [4,5], double [3] or bivalent [8] enkephalins which contain bridges of various type and length between two active peptide fragments belong to this class of compounds. The nature of a bridge can alter, both, biological activity and selectivity toward opioid receptors of an analogue due to increase of enzymatic resistance and possibility of simultaneous interaction with two receptor sites.

Shimohigashi et al. [4,5] have synthesized dimeric analogues of enkephalins in which two peptide fragments were connected at the C-terminus by α,ω-diaminoalkanes of variable length. The analogues exhibited generally high selectivity for δ receptors, and the authors suggested that such dimers could serve as bivalent ligands binding simultaneously to two distinct and closely clustered δ receptors. Lipkowski et al. [3,9] have shown that even a shorter bivalent enkephalin analogue with a dihydrazide bond possessed relatively high activity and also δ receptor selectivity.

Recently, in an effort to reduce the conformational flexibility and to obtain more selective active compounds, a number of laboratories [10–12] have developed glycosylated enkephalin analogues which contained a sugar moiety linked to a peptide pharmacophore through various chemical bonds and showed high biological activities.

The above observations encouraged us [13] to synthesize two dimeric enkephalin analogues with hydrophilic bridges derived from 1,4-diamino-1,4-dideoxy- and 1,6-diamino-1,6-dideoxyalditols bearing two and four vicinal hydroxyl groups, respectively. These closely related analogues expressed comparable affinity for δ receptors but displayed significant differences in binding affinity for μ and κ receptors. The shorter spacer resulted in analogue with selectivity and high affinity for μ and κ receptors.

In the present study we report the syntheses of three new analogues within this series. The short spacers having one or two hydroxyl groups of various configuration have been used for bridging two peptide pharmacophores. The effect of length as well as configuration of a spacer on selectivity of a bivalent opioid ligand was of interest in this study.

Abbreviations: DCC, N,N′-dicyclohexyldiimid; DCCU, N,N′-dicyclohexylurea; BOC, tert-butyloxycarbonyl; CICO0′Bu, isobutyl chloroformate; DADLE, [D-Ala2,D-Leu5]enkephalin; DMF, N,N'-dicyclohexylformamide; HOBt, 1-hydroxybenzotriazole, NMM, N-methylmorpholine.
* Reprint requests to Dr. J. Stepiński.
Verlag der Zeitschrift für Naturforschung, D-72072 Tübingen 0932–0776/94/0300–0407/$ 01.00/0

Dieses Werk wurde im Jahr 2013 vom Verlag Zeitschrift für Naturforschung in Zusammenarbeit mit der Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. digitalisiert und unter folgender Lizenz veröffentlicht: Creative Commons Namensnennung 4.0 Lizenz.
Experimental

Chemical synthesis

Thin layer chromatography (TLC) was performed on silica gel (Kieselgel G, Merck) using the following solvent systems (v/v): (A) isopropanol: triethylamine: water = 7:1:2, (B) n-butanol: acetic acid: water = 4:1:2 (lower phase), (C) chloroform: methanol: benzene: 6.5 N NH₃ aq. = 6:5:4:1.

The ¹³C NMR spectra were obtained with a Jeol FX 90 Q spectrometer. The liquid matrix secondary ions mass spectrometry (LSIMS) was performed on an AMD-604 Intectra GmbH spectrometer. Analytical HPLC analyses were performed on a Spectra-Physics SP 8800 liquid chromatograph, utilizing an analytical Supelco LC-18-T (25 cm, 5 μm, with a 2 cm guard) reversed phase column. The solvent system was buffer A (0.01 M KH₂PO₄, pH 3.0) and buffer B (50% buffer A/50% acetonitrile, v/v). The linear gradient was 40–100% B in 20 min, the flow rate 2.0 ml/min, and monitoring was performed at 210 nm. Semipreparative HPLC was performed on a Supelco LC-18-DB reverse phase column with linear gradients of buffer A (0.03 M ammonium acetate, pH 5.0) and buffer B (33% buffer A/67% acetonitrile, v/v) and monitoring at 230 or 260 nm.

1. 1,3-Diamino-2-propanol dihydrobromide (1), 1,4-diamino-(2R,3S)-butanediol dihydrobromide (2) and 1,4-diamino-(2R,3R)-butanediol dihydrochloride (3) were prepared according to known procedures [14–16] from 1,3-dichloro-2-propanol [17], 1,2-dichloro-1,2-dideoxy-meso-erythritol [18] and D-tartaric acid, respectively. Their ¹³C NMR chemical shifts are given in Table I.

2. 1,3-Di-phenylalanylamido-2-propanol dihydrochloride (4), 1,4-di-phenylalanylamido-(2R,3S)-butanediol dihydrochloride (5) and 1,4-di-phenylalanylamido-(2R,3R)-butanediol dihydrochloride (6) were prepared from appro-

Table I. ¹³C NMR data assignments for characteristic carbon atoms in intermediates: 1 – 6, 7a, 8a and 9a (δ in ppm).

<table>
<thead>
<tr>
<th>Comp.</th>
<th>Solvent</th>
<th>Bridge carbons</th>
<th>Boc</th>
<th>Phe* CH</th>
<th>CH₂</th>
<th>Ar</th>
<th>Tyr* CH</th>
<th>CH₂</th>
<th>Ar</th>
<th>Ala* CH</th>
<th>CH₃</th>
<th>Gly* CH₂</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>D₂O</td>
<td>65.1</td>
<td>43.1</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>2</td>
<td>D₂O</td>
<td>69.7</td>
<td>42.4</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>3</td>
<td>D₂O</td>
<td>68.9</td>
<td>42.7</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>4</td>
<td>D₂O</td>
<td>68.6</td>
<td>43.2</td>
<td>–</td>
<td>55.3</td>
<td>37.6</td>
<td>134.6</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>5</td>
<td>D₂O</td>
<td>71.6</td>
<td>71.4</td>
<td>–</td>
<td>55.4</td>
<td>37.7</td>
<td>134.6</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>6</td>
<td>D₂O</td>
<td>70.4</td>
<td>42.9</td>
<td>–</td>
<td>55.3</td>
<td>37.7</td>
<td>134.7</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>7a</td>
<td>CD₃OD</td>
<td>69.9</td>
<td>43.8⁷</td>
<td>80.9</td>
<td>28.8</td>
<td>56.6</td>
<td>38.6⁴</td>
<td>138.5</td>
<td>58.1</td>
<td>38.6⁴</td>
<td>157.3⁶</td>
<td>e</td>
</tr>
<tr>
<td>8a</td>
<td>DMSO-d₆</td>
<td>71.3</td>
<td>71.0</td>
<td>–</td>
<td>155.0</td>
<td>54.0</td>
<td>137.7</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>9a</td>
<td>CD₃OD</td>
<td>71.0</td>
<td>43.8⁷</td>
<td>80.8</td>
<td>28.7</td>
<td>56.5</td>
<td>38.5⁴</td>
<td>138.4</td>
<td>57.9</td>
<td>38.5⁴</td>
<td>157.6⁶</td>
<td>e</td>
</tr>
</tbody>
</table>

⁷ Signals for carbonyl carbon atoms were observed but not assigned; b, d, f, i signals overlapped; e signal not observed because of overlapping with strong solvent lines; c, g, h assignments may be reversed.
priate diamines (1–3) and Boc-L-phenylalanine by the DCC-catalyzed coupling reaction in DMF as previously described [13] and subsequent deprotection with 4 N HCl in ethyl acetate at room temperature for 1 h. $^{13}$C NMR chemical shifts for compounds 4–6 are shown in Table I.

3. The tripeptide Boc–Tyr–D-Ala–Gly was prepared according to Lipkowski et al. [3].

4. 1,3-Di-(tyrosyl-D-alanyl-glycyl-phenylalanyl-amido)-2-propanol (7b). A solution of Boc–Tyr–D-Ala–Gly (409 mg, 1 mmol) in DMF (2 ml) was placed on a magnetic stirrer, cooled to $-20 \degree C$ and neutralized with NMM (0.11 ml, 1 mmol); then isobutyl chloroformate (0.136 ml, 1 mmol) was added. The temperature of the reaction mixture was maintained at $-20 \degree C$ to $-15 \degree C$ for 15 min, and then a solution of compound 4 (0.5 mmol) with NMM (0.11 ml, 1 mmol) in DMF (5 ml) was added. The stirring was continued for 1 h at room temperature. At that time, the mixture was concentrated (1 mm Hg) and taken up with four 50 ml portions of slightly warmed ethyl acetate. The organic extracts were washed with 10% citric acid, 10% NaCl, saturated NaHCO$_3$ solution, water and dried over anhydrous Na$_2$SO$_4$. The solution was concentrated and the residue purified on a Sephadex G-25 column using $n$-butanol – acetic acid – water (4:1:5, upper phase) as solvent. Fractions containing compound 7b were pooled and lyophilized (85 mg, 60.7%).

Analytical HPLC of 7b revealed single peak (97.6% by integration), retention time: 11.3 min. LSIMS[M$^+$] 997. TLC data: $R_s(A)$ 0.62, $R_s(B)$ 0.29, $R_s(C)$ 0.65. Amino acid analysis: Gly 0.97, Ala 0.97, Tyr 0.89, Phe 1.14.

For the receptor binding assay purpose, an analytical sample of the compound 7b was obtained by additional semipreparative HPLC purification.

5. 1,4-Di-(tyrosyl-D-alanyl-glycyl-phenylalanyl-amido)-(2R,3R)-butanediol (8b). The coupling reaction of Boc–Tyr–D-Ala–Gly (1 mmol) with compound 5 (0.5 mmol) was carried out in the same way as described above for compound 7a. The obtained DMF solution was poured into a chilled mixture of 10% citric acid (30 ml) and 10% NaCl solution (30 ml) with stirring. The precipitation was filtered and washed successively with water, saturated NaHCO$_3$ solution and water. Recrystallization from a relatively big volume of ethyl acetate (200 ml) gave 276 mg (46.1%) of 8a. $^{13}$C NMR chemical shifts for the compound are shown in Table I. After treatment of compound 8a (24 mg, 0.02 mmol) with 4 N HCl in ethyl acetate at room temperature for 1 h, semipreparative HPLC purification and lyophilization, compound 8b (17 mg, 85%) was obtained in pure form.

Analytical HPLC of 8b gave single peak (100% by integration), retention time: 11.1 min. LSIMS[M$^+$] 997. TLC data: $R_s(A)$ 0.64, $R_s(B)$ 0.32, $R_s(C)$ 0.64. Amino acid analysis: Gly 1.06, Ala 1.03, Tyr 0.92, Phe 0.98.

6. 1,4-Di-(tyrosyl-D-alanyl-glycyl-phenylalanyl-amido)-(2R,3R)-butanediol (9b). Compound 9a was prepared from the Boc-tripeptide (1 mmol) and compound 6 (0.5 mmol) in the same manner as described above for compound 8a. Yield: 276 mg (46.1%). $^{13}$C NMR chemical shifts for this compound are shown in Table I. Compound 9a (24 mg, 0.02 mmol) was deprotected with 4 N HCl in ethyl acetate, and the resulted product was purified by semipreparative HPLC. After lyophilization, compound 9b (9 mg, 45%) was obtained in pure form.

Analytical HPLC of 9b gave single peak (97.7% by integration), retention time: 10.6 min. LSIMS[M$^+$] 997. TLC data: $R_s(A)$ 0.62, $R_s(B)$ 0.31, $R_s(C)$ 0.61. Amino acid analysis: Gly 1.04, Ala 1.08, Tyr 0.93, Phe 0.94.

Receptor binding assays

Brains were dissected from decapitated male Hartley guinea pigs. Brain membranes preparation and receptor binding assays were performed as described previously [19, 20]. The final concentration of labelled ligands used were: 0.5 nM $[^3H]$naloxone ($\mu$ binding); 1 nM $[^3H]$DADLE in the presence of 4 nM sufentanil ($\delta$ binding); and 1 nM (−)$[^3H]$ethylketocyclazocine (EKC) in the presence of 500 nM DADLE and 20 nM sufentanil (κ binding). Under these conditions, the apparent $K_s$s for $[^3H]$naloxone, $[^3H]$DADLE, and (−)$[^3H]$EKC were 0.98, 0.64 and 0.62, respectively. Binding was performed with 100 mM NaCl and bacitracin (50 μg/ml). $IC_{50}$s were calculated from log–logit plots. Apparent $K_s$s were calculated from the equation, $K_s = IC_{50}/[1 + (L/K_d)]$, where L is the concentration of the radioligand and $K_d$ is its dissociation constant. The results are shown in Table II.

For the receptor binding assay purpose, an analytical sample of the compound 7b was obtained by additional semipreparative HPLC purification.

5. 1,4-Di-(tyrosyl-D-alanyl-glycyl-phenylalanyl-amido)-(2R,3R)-butanediol (8b). The coupling reaction of Boc–Tyr–D-Ala–Gly (1 mmol) with compound 5 (0.5 mmol) was carried out in the same way as described above for compound 7a. The obtained DMF solution was poured into a chilled mixture of 10% citric acid (30 ml) and 10% NaCl solution (30 ml) with stirring. The precipitation was filtered and washed successively with water, saturated NaHCO$_3$ solution and water. Recrystallization from a relatively big volume of ethyl acetate (200 ml) gave 276 mg (46.1%) of 8a. $^{13}$C NMR chemical shifts for the compound are shown in Table I. After treatment of compound 8a (24 mg, 0.02 mmol) with 4 N HCl in ethyl acetate at room temperature for 1 h, semipreparative HPLC purification and lyophilization, compound 8b (17 mg, 85%) was obtained in pure form.

Analytical HPLC of 8b gave single peak (100% by integration), retention time: 11.1 min. LSIMS[M$^+$] 997. TLC data: $R_s(A)$ 0.64, $R_s(B)$ 0.32, $R_s(C)$ 0.64. Amino acid analysis: Gly 1.06, Ala 1.03, Tyr 0.92, Phe 0.98.

6. 1,4-Di-(tyrosyl-D-alanyl-glycyl-phenylalanyl-amido)-(2R,3R)-butanediol (9b). Compound 9a was prepared from the Boc-tripeptide (1 mmol) and compound 6 (0.5 mmol) in the same manner as described above for compound 8a. Yield: 276 mg (46.1%). $^{13}$C NMR chemical shifts for this compound are shown in Table I. Compound 9a (24 mg, 0.02 mmol) was deprotected with 4 N HCl in ethyl acetate, and the resulted product was purified by semipreparative HPLC. After lyophilization, compound 9b (9 mg, 45%) was obtained in pure form.

Analytical HPLC of 9b gave single peak (97.7% by integration), retention time: 10.6 min. LSIMS[M$^+$] 997. TLC data: $R_s(A)$ 0.62, $R_s(B)$ 0.31, $R_s(C)$ 0.61. Amino acid analysis: Gly 1.04, Ala 1.08, Tyr 0.93, Phe 0.94.
Table II. Affinities of bivalent enkephalin analogues for \( \mu, \delta \) and \( \kappa \) opioid receptors.

<table>
<thead>
<tr>
<th>Comp. No.</th>
<th>Compound structure</th>
<th>Bridge configur.</th>
<th>( K_i ) [nM]</th>
<th>( \delta )</th>
<th>( \kappa )</th>
</tr>
</thead>
<tbody>
<tr>
<td>10b</td>
<td>(Tyr - D-Ala - Gly - Phe - NH -)2</td>
<td></td>
<td>12 ± 2</td>
<td>4.6 ± 0.2</td>
<td>270 ± 15</td>
</tr>
<tr>
<td>7b</td>
<td>(Tyr - D-Ala - Gly - Phe - NH - CH2 -)2 CHO H</td>
<td>erythro (R,S)</td>
<td>62 ± 11</td>
<td>82 ± 7</td>
<td>90 ± 7</td>
</tr>
<tr>
<td>8b</td>
<td>(Tyr - D-Ala - Gly - Phe - NH - CH2 - CHOH -)2</td>
<td>D-threo (R,R)</td>
<td>69 ± 17</td>
<td>44 ± 6</td>
<td>137 ± 23</td>
</tr>
<tr>
<td>9b</td>
<td>(Tyr - D-Ala - Gly - Phe - NH - CH2 - CHOH -)2</td>
<td>L-threo (S,S)</td>
<td>71 ± 23</td>
<td>10 ± 2</td>
<td>74 ± 8</td>
</tr>
<tr>
<td>11c</td>
<td>(Tyr - D-Ala - Gly - Phe - NH - CH2 - CHOH -)2</td>
<td></td>
<td>3.2 ± 1.2</td>
<td>18 ± 5</td>
<td>1.8 ± 1</td>
</tr>
</tbody>
</table>

\( a \) Data represent mean ± S.E.M. of 3–4 experiments in duplicate; \( b \) reference [9]; \( c \) reference [13].

Results and Discussion

The syntheses of the new three dimeric enkephalin analogues 7b, 8b and 9b were carried out according to our previously reported strategy [13]. The synthetic route is outlined in Fig. 1. The two diamine synthons 1 and 2 were prepared by means of Gabriel reaction [14] from glycerol and meso-erythritol via their dichlorodideoxy derivatives [17,18]. Compound 3 was synthesized from D-tartaric acid in few steps as described by Kiely et al. [16] for the L enantiomer. Analytical data for the diamines in appropriate forms of dihydrohalides were in good accord with the expected structures. Coupling reactions of the above diamines with N-protected phenylalanine were carried out in DMF using the DCC-HOBt method. The coupling products exhibited very low solubility in water and any inert organic solvent. Their NMR spectra were taken after deprotection of the amino groups (Table I, compounds: 4, 5 and 6). Next, the mixed anhydride method was used for the connection of the N-Boc protected tripeptide with the phenylalanine residues. Attempts to use the DCC-HOBt coupling method on this stage have also been made, but they indicated poorer performance in relation to the mixed anhydride synthesis due to, both, yield and purity of the crude products. Target dimeric analogues were obtained after deprotection of the Boc group, chromatographic purification and lyophilization. Products 7b, 8b and 9b were obtained as fine, white powdery compounds with the correct amino acid analyses and LSIMS spectra. Analytical HPLC gave single peaks for these substances.

The dimeric analogues were tested for receptor binding to \( \mu, \delta \) and \( \kappa \) receptors in guinea pig brain homogenates by the methodology identical with that used previously for characterization of other bivalent ligands [9,13]. The \( K_i \) values are presented in Table II. All three newly synthesized analogues exhibit different affinity profiles toward opioid receptors.
receptors. Extension of the spacer length between the tetrapeptide pharmacophores of model compound 10 [3, 9] by three or four carbons containing one and two hydroxyl groups, respectively (compounds 7b, 8b and 9b), in general increased \( \kappa \) receptor affinity and decreased \( \delta \) and \( \mu \) receptor affinity. The \( R,S \) spacer configuration produced a non-selective compound (8b) with moderate affinity for all 3 opioid receptor types. The \( R,R \) spacer configuration produced a compound (9b) with high affinity and relative \( \delta \) selectivity. The change of spacer configuration \( R,R \) to \( S,S \) (or D to L, compound 9b and 11, respectively) resulted in an about 20 times increase in the affinity for \( \mu \) receptors and an even more spectacular increase of 40 times for \( \kappa \) receptors, while the affinity for \( \delta \) receptors was not significantly affected. Thus, both, the length and configuration of the spacer are important factors in determining receptor potency and selectivity within this series.

It thus appears that the use of hydrophilic spacers creates new possibilities in the modulation of activity and selectivity of opioid peptide bivalent ligands.

This research was partially conducted within the Project Numbers BW-550/91 and BW-662/9/92.